Kane Biotech Inc KNBIF

Primary Symbol: V.KNE

Healthcare Biotechnology

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.

TSXV:KNE - Post by User

Kane Biotech Inc > Cash available vs expenses

<< Previous

Bullboard Posts

Next >>

Comment by KevinOlearyon Aug 30, 2024 8:24pm

70 Views

Post# 36203643

RE:RE:RE:RE:RE:Cash available vs expenses

There are too many things going on for me to have a clue what their short term cash needs will be. They have done lots of financings, so they know not to leave it to the last minute which makes me think there is going to be enough cash coming in to sustain them.
There aren't any European companies in their Revyve distributor list so they may be looking for a big one who would provide an upfront payment. Who knows?

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta